Unknown

Dataset Information

0

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.


ABSTRACT: The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.

SUBMITTER: Sharif S 

PROVIDER: S-EPMC2588473 | biostudies-literature | 2008 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.

Sharif Saima S   O'Connell Michael J MJ   Yothers Greg G   Lopa Samia S   Wolmark Norman N  

Cancer investigation 20081101 9


The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to  ...[more]

Similar Datasets

| S-EPMC7747753 | biostudies-literature
| S-EPMC10932665 | biostudies-literature
| S-EPMC4412676 | biostudies-literature
| S-EPMC6507487 | biostudies-literature
| S-EPMC10417185 | biostudies-literature
| S-EPMC6426127 | biostudies-literature
| S-EPMC6002808 | biostudies-literature
| S-EPMC4497499 | biostudies-literature
2017-05-31 | GSE83889 | GEO
| S-EPMC5503619 | biostudies-literature